Israël - Hebreeuws - Ministry of Health

dexcel ltd, israel - dextromethorphan hydrobromide; guaifenesin; paracetamol; pseudoephedrine hydrochloride - קפליות - paracetamol 325 mg; guaifenesin 200 mg; dextromethorphan hydrobromide 10 mg; pseudoephedrine hydrochloride 25 mg - dextromethorphan - dextromethorphan - for the symptomatic relief of cold, cough and nasal congestion accompanied by fever and pain, for day care.

Israël - Hebreeuws - Ministry of Health

novartis israel ltd - glycopyrronium as bromide; indacaterol as maleate - אבקה לשאיפה בקפסולות קשיחות - indacaterol as maleate 110 mcg; glycopyrronium as bromide 50 mcg - indacaterol

Israël - Hebreeuws - Ministry of Health

dexcel ltd, israel - paracetamol; pseudoephedrine hydrochloride - קפליות - paracetamol 500 mg; pseudoephedrine hydrochloride 25 mg - pseudoephedrine, combinations

Israël - Hebreeuws - Ministry of Health

dexcel ltd, israel - isosorbide mononitrate - טבליות בשחרור איטי - isosorbide mononitrate 50 mg - isosorbide mononitrate

Israël - Hebreeuws - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 25 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israël - Hebreeuws - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israël - Hebreeuws - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

Israël - Hebreeuws - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

Israël - Hebreeuws - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

Israël - Hebreeuws - Ministry of Health

taro pharmaceutical industries ltd - etodolac - טבליות עם שחרור נרחב - etodolac 600 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis.